Scribe Therapeutics insider reports holdings

Scribe Therapeutics, Inc. insider Brett Staahl, reported as a ten percent owner, filed an initial statement of beneficial ownership.

Accepted by SEC EDGAR 07/23/2026 - 09:28 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Scribe Therapeutics, Inc. insider Brett Staahl, reported as a ten percent owner, filed an initial statement of beneficial ownership. He holds 524,336 shares of Common Stock directly. In addition, he reports four stock option awards over Common Stock with exercise prices of $3.08, $6.40 and $19.13, covering 2,462, 17,798, 4,755 and 1,688 underlying shares, expiring between 2030 and 2036. Certain options are fully vested, while one grant began vesting 25% on January 1, 2026 with the remainder vesting in equal monthly installments subject to continued service.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Staahl Brett

Role 10% Owner

Type	Security	Shares	Price	Value
Holding	Stock Option (Right to Buy) F1	--	--	--
Holding	Stock Option (Right to Buy) F1	--	--	--
Holding	Stock Option (Right to Buy) F1	--	--	--
Holding	Stock Option (Right to Buy) F2	--	--	--
Holding	Common Stock	--	--	--

Holdings: Stock Option (Right to Buy) — 26,703 contracts (Direct); Common Stock — 524,336 shares (Direct)

Footnotes (2)

1. F1. The option is fully vested.
2. F2. The options vested as to 25% of the award on January 1, 2026, and the remaining 75% of the option will vest in equal monthly installments thereafter until such time as the options are 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Common Stock held: 524,336 shares Option exercise price: $3.08 per share Option exercise price: $6.40 per share +3 more

6 metrics

Common Stock held 524,336 shares Directly owned Common Stock reported by Brett Staahl

Option exercise price $3.08 per share Stock Option (Right to Buy) over 2,462 underlying Common shares, expiring 2030-06-07

Option exercise price $6.40 per share Stock Option over 17,798 underlying Common shares, expiring 2031-08-05

Option exercise price $19.13 per share Stock Option over 4,755 underlying Common shares, expiring 2036-03-12

Partially vesting option 1,688 underlying shares Stock Option at $6.40 expiring 2035-03-20 with staged vesting from January 1, 2026

Ten percent owner status Yes Reporting person classified as ten percent owner of Scribe Therapeutics

Key Terms

Stock Option (Right to Buy), underlying security, vested, beneficial ownership

4 terms

Stock Option (Right to Buy) financial

"He reports four Stock Option (Right to Buy) positions over Common Stock"

underlying security financial

"each option lists an underlying security title of Common Stock"

vested financial

"The option is fully vested and another grant vested 25% on January 1, 2026"

beneficial ownership financial

"filed an initial statement of beneficial ownership as a ten percent owner"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for SCTX by Brett Staahl disclose?

The Form 3 shows that Brett Staahl, a ten percent owner of Scribe Therapeutics (SCTX), holds 524,336 common shares directly plus several stock option awards over additional common shares with varying exercise prices and expirations.

How many Scribe Therapeutics (SCTX) common shares does Brett Staahl hold?

Brett Staahl reports direct ownership of 524,336 shares of Common Stock of Scribe Therapeutics (SCTX). This figure represents his reported direct beneficial ownership as of the Form 3 filing date.

What stock options over Scribe Therapeutics (SCTX) does Brett Staahl report?

He reports four Stock Option (Right to Buy) positions over SCTX Common Stock, covering 2,462, 17,798, 4,755 and 1,688 underlying shares, with exercise prices of $3.08, $6.40 and $19.13, expiring between 2030 and 2036.

Are any of Brett Staahl’s Scribe Therapeutics (SCTX) options fully vested?

Yes. A footnote states that certain options are fully vested. Another grant vested 25% on January 1, 2026, with the remaining 75% vesting in equal monthly installments, subject to continued service to Scribe Therapeutics.

Does the SCTX Form 3 show recent buy or sell transactions by Brett Staahl?

No buy or sell transactions are indicated. The entries are reported as holdings, listing existing Common Stock and stock option positions, rather than new purchases, sales, or exercises on the transaction date.

Why is Brett Staahl classified as a ten percent owner of Scribe Therapeutics (SCTX)?

The Form 3 designates him as a ten percent owner, meaning his reported beneficial holdings meet the SEC threshold for that status, which requires initial reporting of his Scribe Therapeutics equity positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Staahl Brett

(Last) (First) (Middle)

C/O SCRIBE THERAPEUTICS INC.

1150 MARINA VILLAGE PARKWAY

(Street)

ALAMEDA CALIFORNIA 94501

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/23/2026

3. Issuer Name and Ticker or Trading Symbol
Scribe Therapeutics, Inc. [ SCTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	524,336	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	06/07/2030	Common Stock	2,462	$3.08	D
Stock Option (Right to Buy)	(1)	08/05/2031	Common Stock	17,798	$6.4	D
Stock Option (Right to Buy)	(1)	03/12/2036	Common Stock	4,755	$19.13	D
Stock Option (Right to Buy)	(2)	03/20/2035	Common Stock	1,688	$6.4	D

Explanation of Responses:

1. The option is fully vested.

2. The options vested as to 25% of the award on January 1, 2026, and the remaining 75% of the option will vest in equal monthly installments thereafter until such time as the options are 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Brett Staahl	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)